Celyad Oncology SA
CLYYF
$0.20
-$0.21-51.22%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.03M | -6.58M | -6.30M | -7.35M | -8.39M |
| Total Depreciation and Amortization | 370.40K | 377.80K | 394.80K | 497.80K | 600.40K |
| Total Amortization of Deferred Charges | 92.00K | 92.00K | 92.00K | 84.90K | 76.80K |
| Total Other Non-Cash Items | 5.20K | -70.80K | -139.60K | 132.40K | 409.20K |
| Change in Net Operating Assets | -103.60K | -148.00K | -191.60K | -1.69M | -3.20M |
| Cash from Operations | -6.67M | -6.33M | -6.14M | -8.32M | -10.50M |
| Capital Expenditure | -- | -- | -- | -313.80K | -631.10K |
| Sale of Property, Plant, and Equipment | 16.20K | 16.20K | 16.20K | 22.20K | 28.10K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | -63.50K | -127.50K | -128.00K | -128.50K |
| Cash from Investing | 16.20K | -47.30K | -111.30K | -419.70K | -731.60K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -157.00K | -162.00K | -167.00K | -151.50K | -136.00K |
| Issuance of Common Stock | -- | -- | -- | 4.75M | 9.49M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 829.00K | 1.99M | 3.15M | 2.71M | 2.28M |
| Cash from Financing | 726.00K | 1.97M | 3.23M | 7.89M | 12.59M |
| Foreign Exchange rate Adjustments | -3.20K | -3.80K | -4.30K | -2.20K | 0.00 |
| Miscellaneous Cash Flow Adjustments | 0.00 | 100.00 | 100.00 | -400.00 | -1.00K |
| Net Change in Cash | -5.93M | -4.41M | -3.03M | -861.40K | 1.36M |